PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool

Several developments have facilitated the practical application and increased the general use of optimal design for nonlinear mixed effects models. These developments include new methodology for utilizing advanced pharmacometric models, faster optimization algorithms and user friendly software tools. In this paper we present the extension of the optimal design software PopED, which incorporates many of these recent advances into an easily useable enhanced GUI. Furthermore, we present new solutions to problems related to the design of experiments such as: faster and more robust FIM calculations and optimizations, optimizing over cost/utility functions and diagnostic tools and plots to evaluate design performance. Examples for; (i) Group size optimization and efficiency translation, (ii) Cost/constraint optimization, (iii) Optimizations with different FIM approximations and (iv) optimization with parallel computing demonstrate the new features in PopED and underline the potential use of this tool when designing experiments.

[1]  Andrew C. Hooker,et al.  Simultaneous optimal experimental design on dose and sample times , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  C. G. Broyden.  The Convergence of a Class of Double-rank Minimization Algorithms 1. General Considerations , 1970 .

[3]  France Mentré,et al.  Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.

[4]  J. Box.  R.A. Fisher and the Design of Experiments, 1922–1926 , 1980 .

[5]  M. Karlsson,et al.  Ethically Attractive Dose‐Finding Designs for Drugs With a Narrow Therapeutic Index , 2012, Journal of clinical pharmacology.

[6]  Leon Aarons,et al.  Bayesian Optimal Designs for Pharmacokinetic Models: Sensitivity to Uncertainty , 2007, Journal of biopharmaceutical statistics.

[7]  Joakim Nyberg,et al.  Population Pharmacokinetic Modeling and Optimal Sampling Strategy for Bayesian Estimation of Amikacin Exposure in Critically Ill Septic Patients , 2010, Therapeutic drug monitoring.

[8]  Gordon Graham,et al.  The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments , 2005, Comput. Methods Programs Biomed..

[9]  Rainer Schwabe,et al.  Some Considerations on the Fisher Information in Nonlinear Mixed Effects Models , 2010 .

[10]  T. Csendes.  Developments in Reliable Computing , 2000 .

[11]  France Mentré,et al.  Design in nonlinear mixed effects models: Optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariates , 2007, Statistics in medicine.

[12]  Lawrence F. Shampine,et al.  The MATLAB ODE Suite , 1997, SIAM J. Sci. Comput..

[13]  Steven E. Rigdon,et al.  Model-Oriented Design of Experiments , 1997, Technometrics.

[14]  G. Elfving.  Optimum Allocation in Linear Regression Theory , 1952 .

[15]  Erik Sjögren,et al.  Optimal Experimental Design for Assessment of Enzyme Kinetics in a Drug Discovery Screening Environment , 2011, Drug Metabolism and Disposition.

[16]  Gordon Graham,et al.  A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models , 2007, Comput. Methods Programs Biomed..

[17]  Jesús López Fidalgo,et al.  Moda 8 - Advances in Model-Oriented Design and Analysis , 2007 .

[18]  Anthony C. Atkinson,et al.  Optimum Experimental Designs , 1992 .

[19]  Joaquim R. R. A. Martins,et al.  The complex-step derivative approximation , 2003, TOMS.

[20]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[21]  M. D. McKay,et al.  A comparison of three methods for selecting values of input variables in the analysis of output from a computer code , 2000 .

[22]  Valerii V. Fedorov,et al.  Design of experiments with unknown parameters in variance , 2002 .

[23]  Andrew C. Hooker,et al.  Robust Population Pharmacokinetic Experiment Design , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[24]  M. Foracchia,et al.  POPED, a software for optimal experiment design in population kinetics , 2004, Comput. Methods Programs Biomed..

[25]  M Tod,et al.  Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria. , 1996, Computer methods and programs in biomedicine.

[26]  D. Bates,et al.  Nonlinear mixed effects models for repeated measures data. , 1990, Biometrics.

[27]  C. R. Rao,et al.  Information and the Accuracy Attainable in the Estimation of Statistical Parameters , 1992 .

[28]  Stephen B. Duffull,et al.  Optimal Design for Model Discrimination and Parameter Estimation for Itraconazole Population Pharmacokinetics in Cystic Fibrosis Patients , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[29]  Stefanie Hennig,et al.  Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin , 2012, Journal of clinical pharmacology.

[30]  Siegfried M. Rump,et al.  INTLAB - INTerval LABoratory , 1998, SCAN.

[31]  E. Walter,et al.  Robust experiment design via stochastic approximation , 1985 .

[32]  Stefanie Hennig,et al.  Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies , 2009, Journal of clinical pharmacology.

[33]  Roger B. Sidje,et al.  Expokit: a software package for computing matrix exponentials , 1998, TOMS.

[34]  W. Magnus.  On the exponential solution of differential equations for a linear operator , 1954 .

[35]  P. Laycock,et al.  Optimum Experimental Designs , 1995 .

[36]  France Mentré,et al.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..

[37]  V. Fedorov,et al.  Invited Discussion Paper Constrained Optimization of Experimental Design , 1995 .

[38]  Yaning Wang.  Derivation of various NONMEM estimation methods , 2007, Journal of Pharmacokinetics and Pharmacodynamics.